$SCLX
Scilex Holding Co Stock $sclx

$sclx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000095017023063810 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$13.46M	$10.12M	$11.92M
YoY Change	12.95%
Cost Of Revenue	$4.521M	$3.392M	$4.513M
YoY Change	0.18%	-46.02%	315.94%
Gross Profit	$8.941M	$6.725M	$7.406M
YoY Change	20.73%	-66.09%	3.18%
Gross Profit Margin	66.42%	66.47%	62.14%
Selling, General & Admin	$23.52M	$40.43M	$23.52M
YoY Change	-0.02%	-2.27%	62.35%
% of Gross Profit	263.06%	601.2%	317.63%
Research & Development	$2.734M	$4.072M	$2.597M
YoY Change	5.28%	-36.94%	19.68%
% of Gross Profit	30.58%	60.55%	35.07%
Depreciation & Amortization	$1.034M	$12.00K	$1.035M
YoY Change	-0.1%	-99.59%	-72.61%
% of Gross Profit	11.56%	0.18%	13.98%
Operating Expenses	$27.28M	$44.50M	$27.15M
YoY Change	0.49%	6665.94%	6953.73%
Operating Profit	-$18.34M	-$38.81M	-$19.74M
YoY Change	-7.1%	5799.69%	-390.6%
Interest Expense	-$3.053M	$513.0K	$1.897M
YoY Change	-260.94%	44315.58%	210677.78%
% of Operating Profit
Other Income/Expense, Net	$0.00	$3.276M
YoY Change		4689.47%
Pretax Income	-$21.39M	-$35.53M	-$17.84M
YoY Change	19.88%	26940.87%	-1675.36%
Income Tax	$8.000K	$0.00	$40.00K
% Of Pretax Income
Net Earnings	-$21.40M	-$35.53M	-$17.88M
YoY Change	19.66%	26941.49%	-1678.9%
Net Earnings / Revenue	-158.97%	-351.18%	-150.05%
Basic Earnings Per Share		-$0.63
Diluted Earnings Per Share	-$0.22	-$0.63	-$0.13
COMMON SHARES
Basic Shares Outstanding	155.9M	149.1M	13.18M shares
Diluted Shares Outstanding		139.8M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.921M	$1.954M	$2.184M
YoY Change	79.53%	5489.24%	329.99%
Cash & Equivalents	$3.900M	$2.000M	$2.184M
Short-Term Investments
Other Short-Term Assets	$4.049M	$3.157M	$4.810M
YoY Change	-15.82%	2313.79%	105847.14%
Inventory	$4.214M	$3.942M	$1.378M
Prepaid Expenses
Receivables	$34.60M	$16.43M	$21.24M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$46.78M	$25.48M	$29.61M
YoY Change	58.0%	15273.25%	5677.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$722.0K	$769.0K	$772.0K
YoY Change	-6.48%	-62.54%	-4.1%
Goodwill	$13.50M	$13.50M	$13.50M
YoY Change	0.0%		0.0%
Intangibles	$36.49M	$37.51M	$40.59M
YoY Change	-10.12%		4.61%
Long-Term Investments
YoY Change
Other Assets	$897.0K	$166.0K	$944.0K
YoY Change	-4.98%	-99.84%	-99.32%
Total Long-Term Assets	$54.53M	$55.05M	$56.92M
YoY Change	-4.2%	-45.66%	-59.17%
TOTAL ASSETS
Total Short-Term Assets	$46.78M	$25.48M	$29.61M
Total Long-Term Assets	$54.53M	$55.05M	$56.92M
Total Assets	$101.3M	$80.53M	$86.53M
YoY Change	17.08%	-20.63%	-38.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.95M	$32.56M	$8.450M
YoY Change	384.66%	3923.28%	3948.87%
Accrued Expenses	$100.5M	$80.30M	$36.13M
YoY Change	178.19%	208.77%
Deferred Revenue
YoY Change
Short-Term Debt	$108.4M	$115.2M	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$250.4M	$228.6M	$44.84M
YoY Change	458.36%	28144.44%	21385.93%
LONG-TERM LIABILITIES
Long-Term Debt	$17.04M	$6.932M	$0.00
YoY Change
Other Long-Term Liabilities	$179.0K	$173.0K	$163.0K
YoY Change	9.82%		2265.06%
Total Long-Term Liabilities	$179.0K	$173.0K	$163.0K
YoY Change	9.82%		2265.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$250.4M	$228.6M	$44.84M
Total Long-Term Liabilities	$179.0K	$173.0K	$163.0K
Total Liabilities	$274.2M	$243.2M	$50.29M
YoY Change	445.35%	1898.54%	444.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$490.2M	-$468.8M	-$375.9M
YoY Change	30.41%	3805.57%	4221.96%
Common Stock	$16.00K	$15.00K	$14.00K
YoY Change	14.29%	4247.83%	3957.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$90.52M	$90.60M	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	-$172.9M	-$162.7M	$36.24M
YoY Change
Total Liabilities & Shareholders Equity	$101.3M	$80.53M	$86.53M
YoY Change	17.08%	-20.63%	-38.16%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$21.40M	-$35.53M	-$17.88M
YoY Change	19.66%	26941.49%	-1678.9%
Depreciation, Depletion And Amortization	$1.034M	$12.00K	$1.035M
YoY Change	-0.1%	-99.59%	-72.61%
Cash From Operating Activities	-$5.390M	$5.900M	-$725.0K
YoY Change	643.45%	-1965.26%	573.04%
INVESTING ACTIVITIES
Capital Expenditures	$167.0K	$155.0K	$0.00
YoY Change		-92.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$167.0K	-$155.0K	$0.00
YoY Change		-100.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.306M	-38.89M	426.0K
YoY Change	1849.77%	-4.8%	-14.8%
NET CHANGE
Cash From Operating Activities	-5.390M	5.900M	-725.0K
Cash From Investing Activities	-167.0K	-155.0K	0.000
Cash From Financing Activities	8.306M	-38.89M	426.0K
Net Change In Cash	2.749M	-33.15M	-299.0K
YoY Change	-1019.4%	10378.96%	-176.22%
FREE CASH FLOW
Cash From Operating Activities	-$5.390M	$5.900M	-$725.0K
Capital Expenditures	$167.0K	$155.0K	$0.00
Free Cash Flow	-$5.557M	$5.745M	-$725.0K
YoY Change	666.48%	-341.05%	573.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001820190
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q3	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2023Q3	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39852
	dei	Entity Registrant Name EntityRegistrantName	Scilex Holding Company
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	92-1062542
	dei	Entity Address Address Line1 EntityAddressAddressLine1	960 San Antonio Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94303
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	516-4310
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	SCLX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	155942986
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1954000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16428000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21236000
CY2023Q3	us-gaap	Inventory Net InventoryNet	3942000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1378000
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3157000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4810000
CY2023Q3	us-gaap	Assets Current AssetsCurrent	25481000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	29608000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	769000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3120000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1131000
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	37511000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40591000
CY2023Q3	us-gaap	Goodwill Goodwill	13481000
CY2022Q4	us-gaap	Goodwill Goodwill	13481000
CY2023Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	166000
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	944000
CY2023Q3	us-gaap	Assets Assets	80528000
CY2022Q4	us-gaap	Assets Assets	86527000
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	32560000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8450000
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3133000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1354000
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	65800000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30893000
CY2023Q3	sclx	Accrued Expenses AccruedExpenses	10575000
CY2022Q4	sclx	Accrued Expenses AccruedExpenses	3136000
CY2023Q3	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	503000
CY2022Q4	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	264000
CY2023Q3	us-gaap	Debt Current DebtCurrent	115222000
CY2022Q4	us-gaap	Debt Current DebtCurrent	0
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	787000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	228580000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44842000
CY2023Q3	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	3014000
CY2022Q4	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	3387000
CY2023Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	6932000
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2096000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1231000
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2402000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	665000
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	173000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2023Q3	us-gaap	Liabilities Liabilities	243197000
CY2022Q4	us-gaap	Liabilities Liabilities	50288000
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	45000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	45000000
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29057097
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29057097
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29057097
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29057097
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154185089
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	500000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133283000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141358000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133049000
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94116504
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141348856
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141348856
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	15000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396762000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412136000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-468845000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375914000
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	60068585
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	90601000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-162669000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36239000
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80528000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86527000
CY2023Q3	us-gaap	Revenues Revenues	10117000
CY2022Q3	us-gaap	Revenues Revenues	11377000
	us-gaap	Revenues Revenues	33281000
	us-gaap	Revenues Revenues	26115000
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3392000
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	3611000
	us-gaap	Cost Of Revenue CostOfRevenue	11160000
	us-gaap	Cost Of Revenue CostOfRevenue	6284000
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4072000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1237000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10012000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6457000
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40431000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16119000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96121000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41371000
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1027000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1026000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3080000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2896000
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	48922000
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	21993000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	120373000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	57008000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-38805000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10616000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-87092000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30893000
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	4245000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1090000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5300000
CY2023Q3	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	449000
CY2022Q3	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	4197000
	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	33433000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
CY2023Q3	us-gaap	Interest Expense InterestExpense	513000
CY2022Q3	us-gaap	Interest Expense InterestExpense	1858000
	us-gaap	Interest Expense InterestExpense	517000
	us-gaap	Interest Expense InterestExpense	8596000
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7000
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	31000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	39000
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3276000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32106000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5834000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25377000
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35529000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21490000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92926000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5516000
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-35529000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	21501000
	us-gaap	Net Income Loss NetIncomeLoss	-92931000
	us-gaap	Net Income Loss NetIncomeLoss	-5480000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139808000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133060000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141358000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133049000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139808000
	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	351000
	us-gaap	Share Based Compensation ShareBasedCompensation	10813000
	us-gaap	Share Based Compensation ShareBasedCompensation	4027000
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	750000
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1090000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36239000
CY2023Q1	sclx	Value Issued Under Standby Equity Purchase Agreements ValueIssuedUnderStandbyEquityPurchaseAgreements	1869000
CY2023Q1	sclx	Retainer Shares Issued Value RetainerSharesIssuedValue	1000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3720000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-30753000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11076000
CY2023Q2	sclx	Value Issued Under Standby Equity Purchase Agreements ValueIssuedUnderStandbyEquityPurchaseAgreements	13925000
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	222000
CY2023Q2	sclx	Conversion Of Convertible Debentures Into Common Stock Value ConversionOfConvertibleDebenturesIntoCommonStockValue	7735000
CY2023Q2	sclx	Issuance Of Common Stock Upon Warrants Exercise Value IssuanceOfCommonStockUponWarrantsExerciseValue	521000
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3587000
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-26649000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10417000
CY2023Q3	sclx	Value Issued Under Standby Equity Purchase Agreements ValueIssuedUnderStandbyEquityPurchaseAgreements	11214000
CY2023Q3	sclx	Disbursement Of Funds To Sorrento Amount DisbursementOfFundsToSorrentoAmount	-20000000
CY2023Q3	sclx	Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue	-143786000
CY2023Q3	sclx	Issuance Of Penny Warrants IssuanceOfPennyWarrants	10401000
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	750000
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	358000
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3506000
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-35529000
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-162669000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-223876000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1355000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-9143000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-231568000
CY2022Q2	sclx	Adjustmenttoadditionalpaidincapitaldiscountamortization Adjustmenttoadditionalpaidincapitaldiscountamortization	-4127000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1437000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-17838000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-252096000
CY2022Q3	sclx	Adjustmenttoadditionalpaidincapitaldiscountamortization Adjustmenttoadditionalpaidincapitaldiscountamortization	-35000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1235000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	21501000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-229395000
	us-gaap	Net Income Loss NetIncomeLoss	-92931000
	us-gaap	Net Income Loss NetIncomeLoss	-5480000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3112000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2926000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	34000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3108000
	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	0
	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	21190000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	330000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5300000
	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	4197000
	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-19000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4808000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3206000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2565000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1629000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1072000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	3478000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-804000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-385000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	11486000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2967000
	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	1779000
	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-2307000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5525000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1373000
	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	34907000
	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	13776000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-519000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-255000
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	0
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	21521000
	sclx	Other Long Term Liabilities OtherLongTermLiabilities	10000
	sclx	Other Long Term Liabilities OtherLongTermLiabilities	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15317000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20533000
	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	134000
	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	2060000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-163000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2067000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27589000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	24000000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10953000
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
	sclx	Proceeds From Issuance Of Revolving Facility ProceedsFromIssuanceOfRevolvingFacility	52550000
	sclx	Proceeds From Issuance Of Revolving Facility ProceedsFromIssuanceOfRevolvingFacility	0
	sclx	Repayment Of Revolving Facility RepaymentOfRevolvingFacility	45272000
	sclx	Repayment Of Revolving Facility RepaymentOfRevolvingFacility	0
	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	1372000
	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	0
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	380000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
	sclx	Disbursement Of Funds DisbursementOfFunds	-20000000
	sclx	Disbursement Of Funds DisbursementOfFunds	0
	us-gaap	Accelerated Share Repurchases Adjustment To Recorded Amount AcceleratedShareRepurchasesAdjustmentToRecordedAmount	-10000000
	us-gaap	Accelerated Share Repurchases Adjustment To Recorded Amount AcceleratedShareRepurchasesAdjustmentToRecordedAmount	0
	sclx	Transaction Costs Paid In Connection With Share Repurchase TransactionCostsPaidInConnectionWithShareRepurchase	1987000
	sclx	Transaction Costs Paid In Connection With Share Repurchase TransactionCostsPaidInConnectionWithShareRepurchase	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1101000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	51900000
	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	0
	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	62500000
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	9857000
	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	0
	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-84808000
	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	0
	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	-18800000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15276000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20745000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-204000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1855000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4338000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1980000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2483000
	us-gaap	Stock Issued1 StockIssued1	1869000
	us-gaap	Stock Issued1 StockIssued1	0
	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	7735000
	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	0
	sclx	Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities With Lease Modification RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification	-2523000
	sclx	Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities With Lease Modification RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification	0
	sclx	Oramed Note Issuance At Fair Value OramedNoteIssuanceAtFairValue	106252000
	sclx	Oramed Note Issuance At Fair Value OramedNoteIssuanceAtFairValue	0
	sclx	Other Non Cash Consideration In Connection With Share Repurchase OtherNonCashConsiderationInConnectionWithShareRepurchase	-26154000
	sclx	Other Non Cash Consideration In Connection With Share Repurchase OtherNonCashConsiderationInConnectionWithShareRepurchase	0
	sclx	Excise Tax In Connection With Share Repurchase Included In Accrued Expenses ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses	1375000
	sclx	Excise Tax In Connection With Share Repurchase Included In Accrued Expenses ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses	0
	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	0
	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	3650000
	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	0
	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	4162000
	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	0
	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	30400000
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	3200000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	26000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1980000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had three customers during the three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each of which individually generated </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company’s total revenue. These customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company’s revenue for the three and nine months ended September 30, 2023, respectively, individually ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. As of September 30, 2023, these customers represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company’s outstanding accounts receivable, individually ranging between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additionally, during the nine months ended September 30, 2023 and 2022, the Company purchased inventory from its sole supplier, Itochu Chemical Frontier Corporation (“Itochu”). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022.</span></p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1954000
	sclx	Treasury Stock Policy Textblock TreasuryStockPolicyTextblock	<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the cost method to account for repurchases of its stock. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares.</span></p>
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000
CY2023Q2	sclx	Principal Laon Amount PrincipalLaonAmount	30000000
	sclx	Outstanding Balance Of Revolving Facility OutstandingBalanceOfRevolvingFacility	6900000
CY2023Q3	sclx	Working Capital WorkingCapital	203100000
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2000000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-87100000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	15300000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-468800000
	sclx	Accrued Royalty Payables AccruedRoyaltyPayables	4000
	sclx	Payment To Acquire License PaymentToAcquireLicense	0
CY2023Q3	us-gaap	Senior Notes SeniorNotes	106252000
CY2023Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	8970000
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	2096000
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	173000
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	117491000
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1231000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1394000
	sclx	Secured Note Discount Rate SecuredNoteDiscountRate	0.1426
	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	25000000
CY2023Q3	sclx	Change In Fair Value Of Convertible Debentures Include Interest Expense ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense	400000
	sclx	Change In Fair Value Of Convertible Debentures Include Interest Expense ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense	4200000
CY2023Q3	sclx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1	0.054
CY2023Q3	sclx	Corporate Bond Yield CorporateBondYield	0.1617
CY2023Q3	sclx	Coupon Interest Rate CouponInterestRate	0.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.70
CY2023Q3	sclx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1	0
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	4200000
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	500000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1100000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5300000
	sclx	Derivative Warrant Liability Private Warrants DerivativeWarrantLiabilityPrivateWarrants	2100000
	sclx	Equity Value EquityValue	1.4
CY2022	sclx	Equity Value EquityValue	3.99
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y1M9D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M9D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0463
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0394
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	sclx	Call Option Value CallOptionValue	0.58
CY2022	sclx	Call Option Value CallOptionValue	0.3
	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	3000000
CY2023Q3	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.108
	sclx	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000
CY2022	sclx	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	968000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	939000
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	199000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	167000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	769000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2023Q3	us-gaap	Depreciation Depreciation	12000
CY2022Q3	us-gaap	Depreciation Depreciation	10000
	us-gaap	Depreciation Depreciation	32000
	us-gaap	Depreciation Depreciation	30000
	sclx	Accrued Expenses Textblock AccruedExpensesTextblock	<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consists of the following (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.28%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:18.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:20.44%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued professional service fees</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4,980</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2,024</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued sales and marketing costs</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,919</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">574</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development costs</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1,641</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">459</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued others</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2,035</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">10,575</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3,136</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4980000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2024000
CY2023Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1919000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	574000
CY2023Q3	sclx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1641000
CY2022Q4	sclx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	459000
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2035000
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	79000
CY2023Q3	sclx	Accrued Expenses AccruedExpenses	10575000
CY2022Q4	sclx	Accrued Expenses AccruedExpenses	3136000
CY2023Q3	us-gaap	Goodwill Goodwill	13500000
CY2022Q4	us-gaap	Goodwill Goodwill	13500000
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60781000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-23270000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37511000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60781000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-20190000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40591000
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y8M12D
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3100000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2900000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1026000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4031000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4006000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4006000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4006000
CY2023Q3	sclx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	20436000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	37511000
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	0
	us-gaap	Notes Issued1 NotesIssued1	24000000
	sclx	Repayment Of Convertible Debentures RepaymentOfConvertibleDebentures	-10953000
	sclx	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures	-3658000
	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	7735000
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	8970000
CY2023Q3	us-gaap	Share Price SharePrice	18
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6854309
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6899988
	us-gaap	Payments Of Dividends PaymentsOfDividends	8650000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	474683
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16939
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38942000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	14820
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.08
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	341
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.7
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	753
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.82
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	30665
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.63
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	423000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17981
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	423000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	48100000
	sclx	Weighted Average Period Over Grant WeightedAveragePeriodOverGrant	P3Y1M6D
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	4000000
CY2023Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	0
CY2022Q3	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0
	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	52645000
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	0
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2500000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2500000
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	0
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000
	us-gaap	Operating Lease Payments OperatingLeasePayments	744000
	us-gaap	Operating Lease Payments OperatingLeasePayments	531000
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.111
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	277000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1042000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	916000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	944000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	724000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3903000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	714000
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3189000
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	787000
CY2023Q3	sclx	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	2402000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-35529000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	21501000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-92931000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5480000
CY2023Q3	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	52645000
	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88174000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21501000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-145576000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5480000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139808000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133060000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141358000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133049000
CY2023Q3	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2022Q3	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	223000
	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139808000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133283000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141358000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133049000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46263476
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27943081

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
sclx-20230930_cal.xml	Edgar Link	unprocessable
sclx-20230930_def.xml	Edgar Link	unprocessable
0000950170-23-063810-index-headers.html	Edgar Link	pending
0000950170-23-063810-index.html	Edgar Link	pending
0000950170-23-063810.txt	Edgar Link	pending
0000950170-23-063810-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sclx-20230930.htm	Edgar Link	pending
sclx-20230930.xsd	Edgar Link	pending
sclx-ex10_12.htm	Edgar Link	pending
sclx-ex10_13.htm	Edgar Link	pending
sclx-ex10_14.htm	Edgar Link	pending
sclx-ex31_1.htm	Edgar Link	pending
sclx-ex31_2.htm	Edgar Link	pending
sclx-ex32_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sclx-20230930_lab.xml	Edgar Link	unprocessable
sclx-20230930_pre.xml	Edgar Link	unprocessable
sclx-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCLX
Scilex Holding Co Stock $sclx

2023 Q4 Form 10-Q Financial Statement

#000095017023063810 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX Scilex Holding Co Stock $sclx

2023 Q4 Form 10-Q Financial Statement

#000095017023063810 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX
Scilex Holding Co Stock $sclx